Immunopathogenesis of thyroid eye disease: emerging paradigms

Surv Ophthalmol. May-Jun 2010;55(3):215-26. doi: 10.1016/j.survophthal.2009.06.009.

Abstract

Graves disease represents a systemic autoimmune process targeting the thyroid, orbit, and pretibial skin. The thyroid dysfunction is treatable, but no consistently effective medical therapy has yet been described for the orbital manifestations of Graves disease, also known as thyroid-associated ophthalmopathy or thyroid eye disease. Several autoantigens are potentially relevant to the pathogenesis of thyroid eye disease. Activating antibodies generated against the thyrotropin receptor can be detected in a majority of patients, and these drive hyperthyroidism. However, stimulating antibodies against the insulin-like growth factor-1 receptor (IGF-1R) may also play a role in the extra-thyroid manifestations of Graves disease. IGF-1R is overexpressed by orbital fibroblasts derived from patients with thyroid eye disease, whereas IGF-1R(+) T and IGF-1R(+) B cells are considerably more frequent in Graves disease. Actions of several cytokines and the molecular interplay peculiar to the orbit appear to provoke the inflammation, fat expansion, and deposition of excessive extracellular matrix molecules in thyroid eye disease. Based upon these new insights, several therapeutic strategies can now be proposed that, for the first time, might specifically interrupt its pathogenesis.

Publication types

  • Review

MeSH terms

  • Autoantigens / immunology
  • Autoimmune Diseases / immunology
  • B-Lymphocytes / immunology*
  • Fibroblasts / metabolism
  • Graves Ophthalmopathy / etiology*
  • Graves Ophthalmopathy / immunology*
  • Humans
  • Orbit / cytology
  • Receptor, IGF Type 1 / metabolism*
  • T-Lymphocytes / immunology*

Substances

  • Autoantigens
  • Receptor, IGF Type 1